𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

✍ Scribed by Tzankov, Alexandar; Xu-Monette, Zijun Y; Gerhard, Marc; Visco, Carlo; Dirnhofer, Stephan; Gisin, Nora; Dybkaer, Karen; Orazi, Attilio; Bhagat, Govind; Richards, Kristy L; Hsi, Eric D; Choi, William WL; van Krieken, J Han; Ponzoni, Maurilio; Ferreri, Andrés JM; Ye, Qing; Winter, Jane N; Farnen, John P; Piris, Miguel A; Møller, Michael B; You, M James; McDonnell, Timothy; Medeiros, L Jeffrey; Young, Ken H

Book ID
125509729
Publisher
Nature Publishing Group
Year
2013
Tongue
English
Weight
461 KB
Volume
27
Category
Article
ISSN
0893-3952

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

CHOP Chemotherapy plus Rituximab Compare
CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma
✍ Coiffier, Bertrand; Lepage, Eric; Brière, Josette; Herbrecht, Raoul; Tilly, Herv 📂 Article 📅 2002 🏛 Massachusetts Medical Society 🌐 English ⚖ 116 KB

## Background The standard treatment for patients with diffuse large-B-cell lymphoma is cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Rituximab, a chimeric monoclonal antibody against the CD20 B-cell antigen, has therapeutic activity in diffuse large-B-cell lymphoma. We conduct